or
Remember me
Back
Such a promising drug..and yet it looks like management will dilute the stock right into the grave. Oh well, not the first time for me having a spec stock go to zero..and likely wont be the last.
Receive investor kits and email updates from Stockhouse and directly from these companies.
At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!